Trial · NCT01416389
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 | LY2523355 + Pegfilgrastim or Filgrastim | -0.0 | Standard Deviation 0.08 | log ratio of end of Cycle 2 to baseline | |
| Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 | Ixabepilone | -0.1 | Standard Deviation 0.37 | log ratio of end of Cycle 2 to baseline | |
| Percentage of Participants Achieving an Overall Response (Overall Response Rate) | LY2523355 + Pegfilgrastim or Filgrastim | 3.8 | 90% Confidence Interval 0.2 to 17 | percentage of responders | |
| Percentage of Participants Achieving an Overall Response (Overall Response Rate) | Ixabepilone | 7.7 | 90% Confidence Interval 0.4 to 31.6 | percentage of responders | |
| Progression-free Survival (PFS) | LY2523355 + Pegfilgrastim or Filgrastim | 1.71 | 90% Confidence Interval 1.25 to 2.79 | months | |
| Progression-free Survival (PFS) | Ixabepilone | 2.76 | 90% Confidence Interval 1.41 to 4.80 | months | |
| Percentage of Participants Achieving a Clinical Benefit (Clinical Benefit Rate) | LY2523355 + Pegfilgrastim or Filgrastim | 46.2 | 90% Confidence Interval 29.2 to 63.8 | percentage of responders | |
| Percentage of Participants Achieving a Clinical Benefit (Clinical Benefit Rate) | Ixabepilone | 61.5 | 90% Confidence Interval 35.5 to 83.4 | percentage of responders | |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 | LY2523355 | Cycle 1, Day 1 | 161 | Geometric Coefficient of Variation 81 | nanograms/milliliter (ng/mL) |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 | LY2523355 | Cycle 1, Day 3 | 150 | Geometric Coefficient of Variation 56 | nanograms/milliliter (ng/mL) |
| Percentage of Deaths on Study Through the Follow-up Period | LY2523355 + Pegfilgrastim or Filgrastim | 7.7 | percentage of participants | ||
| Percentage of Deaths on Study Through the Follow-up Period | Ixabepilone | 15.4 | percentage of participants | ||
| Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LSN2546307 | LSN2546307 | Cycle 1, Day 1 | 5.08 | Geometric Coefficient of Variation 57 | nanograms/milliliter (ng/mL) |
| Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LSN2546307 | LSN2546307 | Cycle1, Day 3 | 5.53 | Geometric Coefficient of Variation 67 | nanograms/milliliter (ng/mL) |
| Pharmacokinetics, Intracycle Accumulation Ration (Ra) of LY2523355 | LY2523355 | 0.92 | Geometric Coefficient of Variation 77 | unitless ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01416389/results